James E. Herndon
Impact in
Papers in
- Co-authors
- Henry S. Friedman (106 shared papers)Allan H. Friedman (63 shared papers)Darell D. Bigner (61 shared papers)David A. Reardon (66 shared papers)Roger E. McLendon (62 shared papers)John Howard Sampson (69 shared papers)Mark R. Green (52 shared papers)James J. Vredenburgh (58 shared papers)
- Journals
- Journal of Clinical Oncology (51 papers)Cancer (40 papers)Neuro-Oncology (23 papers)Journal of Neuro-Oncology (21 papers)Lung Cancer (21 papers)
- Partner nations
- United StatesCanadaUnited Kingdom
In The Last Decade
James E. Herndon
408 papers receiving 41.0k citations
James E. Herndon's Hit Papers
Peers
Comparison fields: 5 of 181
- Genetics 12.4k
- Oncology 11.3k
- Pulmonary and Respiratory Medicine 13.0k
- Cancer Research 5.4k
- Radiology, Nuclear Medicine and Imaging 3.8k
Countries citing papers authored by James E. Herndon
This map shows the geographic impact of James E. Herndon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James E. Herndon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James E. Herndon more than expected).
Fields of papers citing papers by James E. Herndon
This network shows the impact of papers produced by James E. Herndon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James E. Herndon. The network helps show where James E. Herndon may publish in the future.
Co-authors
The 25 scholars most cited alongside James E. Herndon, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 418 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | IDH1 and IDH2 Mutations in Gliomas Hit paper breakdown → | 2009 | 4829 |
| 2 | Bevacizumab Plus Irinotecan in Recurrent Glioblastoma Multiforme Hit paper breakdown → | 2007 | 1168 |
| 3 | Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma Hit paper breakdown → | 2007 | 901 |
| 4 | Improved Survival in Stage III Non-Small-Cell Lung Cancer: Seven-Year Follow-up of Cancer and Leukemia Group B (CALGB) 8433 Trial Hit paper breakdown → | 1996 | 768 |
| 5 | Adjuvant Paclitaxel Plus Carboplatin Compared With Observation in Stage IB Non–Small-Cell Lung Cancer: CALGB 9633 With the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups Hit paper breakdown → | 2008 | 761 |
| 6 | Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma Hit paper breakdown → | 2010 | 674 |
| 7 | Recurrent Glioblastoma Treated with Recombinant Poliovirus Hit paper breakdown → | 2018 | 668 |
| 8 | 2003 | 608 | |
| 9 | Morbidity and Mortality of Major Pulmonary Resections in Patients With Early-Stage Lung Cancer: Initial Results of the Randomized, Prospective ACOSOG Z0030 Trial Hit paper breakdown → | 2006 | 532 |
| 10 | Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors Hit paper breakdown → | 2018 | 514 |
| 11 | 2006 | 511 | |
| 12 | 2006 | 493 | |
| 13 | TERT PROMOTER MUTATIONS OCCUR FREQUENTLY IN GLIOMAS AND A SUBSET OF TUMORS DERIVED FROM CELLS WITH LOW RATES OF SELF-RENEWAL Hit paper breakdown → | 2014 | 470 |
| 14 | Video-Assisted Thoracic Surgery Lobectomy: Report of CALGB 39802—A Prospective, Multi-Institution Feasibility Study Hit paper breakdown → | 2007 | 464 |
| 15 | 2015 | 460 | |
| 16 | 2005 | 451 | |
| 17 | Factors Predictive of Survival Among 337 Patients With Mesothelioma Treated Between 1984 and 1994 by the Cancer and Leukemia Group B Hit paper breakdown → | 1998 | 434 |
| 18 | 2007 | 393 | |
| 19 | 2004 | 371 | |
| 20 | Cardiopulmonary Function and Age-Related Decline Across the Breast Cancer Survivorship Continuum Hit paper breakdown → | 2012 | 362 |
About James E. Herndon
James E. Herndon is a scholar working on Genetics, Oncology, Pulmonary and Respiratory Medicine, Immunology and Neurology, having authored 418 papers that have together received 42.7k indexed citations. Recurring topics across this work include Glioma Diagnosis and Treatment (86 papers), Lung Cancer Diagnosis and Treatment (40 papers), Lung Cancer Research Studies (38 papers), Brain Metastases and Treatment (30 papers), Lung Cancer Treatments and Mutations (25 papers), Cancer survivorship and care (24 papers), Immunotherapy and Immune Responses (21 papers) and Cancer therapeutics and mechanisms (16 papers). The work is most often cited by research in Genetics (12.4k citations), Oncology (11.3k citations), Pulmonary and Respiratory Medicine (13.0k citations), Cancer Research (5.4k citations) and Radiology, Nuclear Medicine and Imaging (3.8k citations). James E. Herndon has collaborated with scholars based in United States, Canada and United Kingdom. Frequent co-authors include Henry S. Friedman, Allan H. Friedman, Darell D. Bigner, David A. Reardon, Roger E. McLendon, John Howard Sampson, Mark R. Green, James J. Vredenburgh, Annick Desjardins and Edward F. Patz. Their work appears in journals such as Journal of Clinical Oncology, Cancer, Neuro-Oncology, Journal of Neuro-Oncology and Lung Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.